Ana Gabrielle Bispo
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Ana Gabrielle Bispo has a total of 7 co-authors. Here are the top co-authors by number of shared publications:
- Brenda Hanae Bentes Koshimoto
Laboratory of Human and Medical Genetics, Federal University of Para, Belem 66075-110, PA, Brazil
1 shared publication - Bruno Lopes Santos-Lobato
Laboratório de Neuropatologia Experimental, Universidade Federal do Pará, Belém, Brazil
1 shared publication - Caio Santos Silva
Universidade federal do Pará
1 shared publication - Camille Sena-Dos-Santos
Laboratory of Human and Medical Genetics, Federal University of Pará, Belém 66075-110, Brazil
1 shared publication - Dafne Dalledone Moura
Graduanda em Medicina Instituição Universidade Federal do Pará (UFPA) Endereço Rua Bernal do Couto 106 Umarizal Belém-PA CEP
1 shared publication - Giovanna Chaves Cavalcante
Departamento de Bioquímica, Instituto de Química, and Centro de Metabolismo CoMeta, Hospital Universitário, Universidade de São Paulo, São Paulo, Brazil
1 shared publication
Latest Publications
- Open Access
- 9 August 2023
- Published by MDPI AG in Biomedicines
- Vol. 11 (8) , 2230
Investigation of PRKN Mutations in Levodopa-Induced Dyskinesia in Parkinson’s Disease Treatment
Mitophagy is an important process that participates in mitochondrial quality control. Dysfunctions in this process can be caused by mutations in genes like PRKN and are associated with the development and progression of Parkinson’s Disease (PD). The most used drug in the treatment of PD is levodopa (LD), but it can cause adverse effects, such as dyskinesia. Currently, few studies are searching for biomarkers for an effective use of lLD for this disease, especially regarding mitophagy genetics. Thus, this work investigates the association of 14 variants of the PRKN gene with LD in the treatment of PD. We recruited 70 patients with PD undergoing treatment with LD (39 without dyskinesia and 31 with dyskinesia). Genotyping was based on Sanger sequencing. Our results reinforce that age at onset of symptoms, duration of PD, and treatment and dosage of LD can influence the occurrence of dyskinesia but not the investigated PRKN variants. The perspective presented here of variants of mitophagy-related genes in the context of treatment with LD is still underexplored, although an association has been indicated in previous studies. We suggest that other variants in PRKN or in other mitophagy genes may participate in the development of levodopa-induced dyskinesia in PD treatment.
- 9 August 2023
- Published by MDPI AG in Biomedicines
- Vol. 11 (8) , 2230
Open AccessInvestigation of PRKN Mutations in Levodopa-Induced Dyskinesia in Parkinson’s Disease Treatment
Mitophagy is an important process that participates in mitochondrial quality control. Dysfunctions in this process can be caused by mutations in genes like PRKN and are associated with the development and progression of Parkinson’s Disease (PD). The most used drug in the treatment of PD is levodopa (LD), but it can cause adverse effects, such as dyskinesia. Currently, few studies are searching for biomarkers for an effective use of lLD for this disease, especially regarding mitophagy genetics. Thus, this work investigates the association of 14 variants of the PRKN gene with LD in the treatment of PD. We recruited 70 patients with PD undergoing treatment with LD (39 without dyskinesia and 31 with dyskinesia). Genotyping was based on Sanger sequencing. Our results reinforce that age at onset of symptoms, duration of PD, and treatment and dosage of LD can influence the occurrence of dyskinesia but not the investigated PRKN variants. The perspective presented here of variants of mitophagy-related genes in the context of treatment with LD is still underexplored, although an association has been indicated in previous studies. We suggest that other variants in PRKN or in other mitophagy genes may participate in the development of levodopa-induced dyskinesia in PD treatment.